ProCE Banner Activity

AUGMENT: Phase III Study of Rituximab/Lenalidomide vs Rituximab/Placebo for R/R Indolent Non-Hodgkin Lymphoma

Slideset Download
Conference Coverage
Combination of rituximab with lenalidomide showed significantly improved disease control vs rituximab alone in this blinded study.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology